semaglutide pioneer Efficacy and safety of oral vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: 12, a double-blind, Phase IIIa, randomised trial | Diabetologia Overview of the PIONEER Clinical

There is also concern among some industry watchers that generic semaglutide could become available in markets where the drug is still patent-protected

As obesity prevalence continues to rise in Korea [2], expanding surgical accesswith appropriate risk stratificationmay yield substantial public health benefits

A meta-analysis summarising studies concerning omega-3 acids published in recent years, which finally included 13 studies covering 127,447 individuals, demonstrated significant reduction of the risk of death due to ischaemic heart disease (risk ratio (RR) = 0.91, 95% CI: 0.850.97, p = 0.010), major vascular events (RR = 0.95, 95% CI: 0.930.98, p = 0.001), nonfatal myocardial infarction (RR = 0.89, 95% CI: 0.830.95, p = 0.001) and all-cause mortality (RR = 0.95, 95% CI: 0.920.99, p = 0.025) [195]

Butler: Marked Expansion of Exocrine and Endocrine Pancreas with Incretin Therapy in Humans with increased Exocrine Pancreas Dysplasia and the potential for Glucagon-producing Neuroendocrine Tumors

But even with half-unit syringes, reconstitution volume matters: a 2mg dose from a 50mg/mL concentration requires 0.04mL (4 units)